Pharmacy Track
 

The IDN pharmacy supply chain plays a vital role in patient outcomes and hospital pharmacy executives continue to look for innovative methods of improving quality while keeping costs low, but the problems facing the pharmacy segment of healthcare are complex.  Topics discussed in the Pharmacy Track will include issues concerning compliance, 503B outsourcing pharmacies, the impacts of the 2019 proposed payment rules and the effect that drug pricing initiatives will have on when and how drugs arrive at your facility, the implications of Part B becoming Part D, and topical ethical dilemmas facing healthcare pharmacists.

 

Monday, September 17, 2018
1:00 PM - 2:15 PM
Grand Canyon 9/10

Healthcare pharmacists are experiencing the effects of the turmoil going on in healthcare today.  New payment models and their impact on patients and the bottom line are a critical issue facing pharmacy professionals.  Traditional formularies and old behaviors and procedures established for the practice or belief at the time often have lingered in place far longer than is prudent.

 

Bonnie Kirschenbaum will examine the impacts of the 2019 proposed payment rules and the effect that drug pricing initiatives will have on when and how drugs arrive at your facility in a variety of ways and from a variety of sources.  Discussion will include the implications of Part B becoming Part D and exploring options for cost savings.  She will help you develop new strategies, question policy, and shake out old habits.  Participants in this session will garner the information they need to look inward to see what they could/should be doing differently to keep pace with change where the focus is on reducing the cost of drugs to the patient.  Come away with insights on how to better know and work with your payors, how to join the rate negotiating team, and how to be prepared to leap ahead into the future with confidence.

 

Learning Objectives:

  1. Determine the impact of new payment models and the idiosyncrasies of working with them.
  2. Examine practical drug procurement and cost solutions.
  3. Develop new strategies that embrace change and question longstanding policy.
 
 
Speaker
Bonnie Kirschenbaum MS, FASHP, FCSHP
Freelance
Consultant, Columnist

 
Moderator
William James Martin Pharm.D.
Vice President Sourcing, Purchasing and Value Analysis
Beaumont Health

Monday, September 17, 2018
2:30 PM - 3:45 PM
Grand Canyon 9/10

As more medications are being individualized and tailored to meet a patient’s individual needs, hospitals are seeing an increase in their reliance on compounding pharmacies.  Forces such as drug shortages, rising costs, and broader questions about safety and risk are resulting in some health systems exploring the opportunity of starting and operating their own 503B Pharmacy. However, there are numerous additional requirements, including stringent equipment, policy, procedural and operational considerations.  Many 503B pharmacies are also falling under increased scrutiny due to the high cost of adhering to FDA’s stringent USP.

 

There are both benefits and risks in operating a 503B facility.   Having the ability to prepare drugs such as sterile injectables, oral formulations, nasal sprays and more in bulk gives hospitals and clinics greater efficiency in the supply chain, can stave off drug shortages, and can lower costs significantly.  Challenges include building and maintaining facilities that are up to USP 797 standards, conducting the ongoing sterility testing required with high-risk compounding, and establishing safe and effective delivery and storage procedures.  This session will explore strategy and implementation for establishing and effectively managing a 503B compounding pharmacy.  Attendees will gain a greater understanding of the financial and operational challenges, the benefits for patients and the organization, and the regulatory and reporting considerations that should be factored into the decision-making process.       

 

Learning Objectives:

  1. Describe the initial development and regulatory journey when starting a 503b compounding pharmacy within a health-system.
  2. Identify the ongoing financial and operational challenges associated with running a 503b registered facility.
  3. Discuss the benefits and risks to patients and the health-system around the various  production models.
 
 
Speaker
Craig Else RPh, PharmD, MHSA
Director of Innovation and Integration for Shared Clinical Services
Fairview Health Services

 
Moderator
Bonnie Kirschenbaum MS, FASHP, FCSHP
Freelance
Consultant, Columnist

Monday, September 17, 2018
4:00 PM - 5:15 PM
Grand Canyon 9/10

Health-system pharmacists face growing ethical challenges as their roles in patient care continue to evolve.  Hospital pharmacies are increasingly experiencing drug shortages with little or no warning, putting patients at risk both physically and mentally.  One of the most exasperating issues facing the United States finds the IDN pharmaceutical supply chain caught in the middle. Opioid abuse is a devastating addiction and forces each of us to address how to deliver proper pain care while balancing the realities of addiction.  The use of Monoclonal Antibodies (MABs) in the treatment of oncology and autoimmune diseases is growing, but the high price tag is often a deterrent to patients who are already financially stressed and must weigh the uncertain benefits against their strapped finances.

 

Solving these types of ethical issues requires manpower, resources, strategy, communication, and planning.  This diverse group of panelists will address these issues and share their unique experiences, challenges and successes in dealing with the daily ethical considerations that face health system pharmacists.

 

Learning Objectives:

  1. Identify tools to manage ethical dilemmas in the hospital pharmacy setting.
  2. Describe the impact that drug shortages are having on hospital pharmacy operations.
  3. Develop new strategies to address the opioid crisis from a pharmacy perspective.
 
Panelists
Melissa Cheeseman Rogers MD
Physician
Veterans Administration Hospital

Ali McBride PharmD, MS
Clinical Coordinator
University of Arizona Cancer Center

Trac Pham
Corporate Director
Advocate Health Care

 
Moderator
Bonnie Kirschenbaum MS, FASHP, FCSHP
Consultant, Columnist
Freelance